Key result
Autologous stem cell transplant carries up to ~47% cumulative 10-year cardiovascular event risk.
Why the study?
The short-term cardiac toxicity of high-dose melphalan with autologous hematopoietic stem cell transplant in patients with multiple myeloma required evaluation.
May warrant long-term CV monitoring after autologous HSCT; leaves open clonal hematopoiesis as a risk stratifier.
The last two decades have seen tremendous progress in the treatment of multiple myeloma, including the use of high-dose melphalan (HDM) with autologous hematopoietic stem cell transplant (auto-HCT)...
No takes yet. Share an insight, caveat, or question.
Gul et al. (2014) conducted a review in Cardiovascular complications and clonal hematopoiesis in autologous hematopoietic stem cell transplantation. Autologous hematopoietic stem cell transplantation (AHSCT) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: